Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Vectura partnership secures $375m COPD (chronic obstructive pulmonary disease) deal:

This article was originally published in Clinica

  • News

Executive Summary

As Clinica went to press today (April 13), UK drug-delivery company Vectura (Chippenham, Wiltshire) and Arakis, its partner in the development of a novel treatment for chronic obstructive pulmonary disease (COPD), announced a $375m global development and commercialisation deal with pharmaceutical giant Novartis. AD 237, a long-acting antimuscarinic agent for treating COPD, uses Vectura's PowderHale inhalation technology. The global COPD drug therapy market is currently worth an estimated $4bn per annum and is expected to grow to $10bn by 2010.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

EU: Good News For IVDs And For Future Transparency Of Medtech Compliance

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

See All
UsernamePublicRestriction

Register

MT054827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By